K. Schutte, J. Bornschein, and P. Malfertheiner, Hepatocellular carcinoma-epidemiological trends and risk factors, Dig Dis, vol.27, pp.80-92, 2009.

J. M. Llovet and J. Bruix, Novel advancements in the management of hepatocellular carcinoma in 2008, J Hepatol, vol.48, issue.1, pp.20-37, 2008.

J. K. Stauffer, A. J. Scarzello, and Q. Jiang, Chronic inflammation, #immune |escape, and oncogenesis in the liver: a unique neighborhood for novel intersections, Hepatology, vol.56, pp.1567-74, 2012.

Q. Gao, S. J. Qiu, and J. Fan, Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection, J Clin Oncol, vol.25, pp.2586-93, 2007.

E. Mizukoshi, Y. Nakamoto, and K. Arai, Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma, Hepatology, vol.53, pp.1206-1222, 2011.

A. Zerbini, M. Pilli, and P. Soliani, Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD81cells in patients with hepatocellular carcinoma, J Hepatol, vol.40, pp.102-111, 2004.

Y. Sawada, T. Yoshikawa, and D. Nobuoka, Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival, Clin Cancer Res, vol.18, pp.3686-96, 2012.

F. Tada, M. Abe, and M. Hirooka, Phase I/II study of immunotherapy using tumor antigenpulsed dendritic cells in patients with hepatocellular carcinoma, Int J Oncol, vol.41, pp.1601-1610, 2012.

T. Takayama, T. Sekine, and M. Makuuchi, Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial, Lancet, vol.356, pp.802-809, 2000.

I. Melero, O. Murillo, and J. Dubrot, Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies, Trends Pharmacol Sci, vol.29, pp.383-90, 2008.

J. C. Hurtado, S. H. Kim, and K. E. Pollok, Potential role of 4-1BB in T cell activation. Comparison with the costimulatory molecule CD28, J Immunol, vol.155, pp.3360-3367, 1995.

J. C. Hurtado, Y. J. Kim, and B. S. Kwon, Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death, J Immunol, vol.158, pp.2600-2609, 1997.

W. W. Shuford, K. Klussman, and D. D. Tritchler, 4-1BB costimulatory signals preferentially induce CD81 T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses, J Exp Med, vol.186, pp.47-55, 1997.

I. Melero, W. W. Shuford, and S. A. Newby, Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors, Nat Med, vol.3, pp.682-687, 1997.

J. A. Kim, B. J. Averbook, and K. Chambers, Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation, Cancer Res, vol.61, pp.2031-2038, 2001.

R. Houot, M. J. Goldstein, and H. E. Kohrt, Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion, Blood, vol.114, pp.3431-3439, 2009.

H. Narazaki, Y. Zhu, and L. Luo, CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells, Blood, vol.115, pp.1941-1949, 2010.

D. Mcilroy, B. Barteau, and J. Cany, DNA/amphiphilic block copolymer nanospheres promote lowdose DNA vaccination, Mol Ther, vol.17, pp.1473-81, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00414626

J. Cany, A. A. Pichard, and V. , A transgenic mouse with beta-Galactosidase as a fetal liver self-antigen for immunotherapy studies, J Hepatol, vol.47, pp.396-403, 2007.

J. Cany, B. Barteau, and L. Tran, AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice, J Hepatol, vol.54, pp.115-136, 2011.

S. Xia, H. Sha, and L. Yang, Gr-11 CD11b1 myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity, J Biol Chem, vol.286, pp.23591-23600, 2011.

I. Melero, S. Hervas-stubbs, and G. M. , Immunostimulatory monoclonal antibodies for cancer therapy, Nat Rev Cancer, vol.7, pp.95-106, 2007.

R. L. Giuntoli, . Ii, J. Lu, and H. Kobayashi, Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function, Clin Cancer Res, vol.8, pp.922-953, 2002.

B. K. Choi, Y. H. Kim, and C. H. Kim, Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma, J Immunol, vol.185, pp.1404-1415, 2010.

S. Gordon, Alternative activation of macrophages, Nat Rev Immunol, vol.3, pp.23-35, 2003.
URL : https://hal.archives-ouvertes.fr/hal-00474829

T. Ding, J. Xu, and F. Wang, High tumorinfiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection, Hum Pathol, vol.40, pp.381-390, 2009.

Y. W. Li, S. J. Qiu, and J. Fan, Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection, J Cancer Res Clin Oncol, vol.135, pp.439-488, 2009.

V. Chew, C. Tow, and M. Teo, Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients, J Hepatol, vol.52, pp.370-379, 2010.

J. Fu, D. Xu, and Z. Liu, Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients, Gastroenterology, vol.132, pp.2328-2367, 2007.

B. Hoechst, L. A. Ormandy, and M. Ballmaier, A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(1)CD25(1)Foxp3(1) T cells, Gastroenterology, vol.135, pp.234-277, 2008.

P. Newell, A. Villanueva, and S. L. Friedman, Experimental models of hepatocellular carcinoma, J Hepatol, vol.48, pp.858-79, 2008.

C. Schneider, A. Teufel, and T. Yevsa, Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer, Gut, vol.61, pp.1733-1776, 2012.

A. Morales-kastresana, M. F. Sanmamed, and I. Rodriguez, Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model, Clin Cancer Res, vol.19, pp.6151-62, 2013.

T. Uno, K. Takeda, and Y. Kojima, Eradication of established tumors in mice by a combination antibody-based therapy, Nat Med, vol.12, pp.693-701, 2006.

A. T. Cheuk, G. J. Mufti, and B. A. Guinn, Role of 4-1BB:4-1BB ligand in cancer immunotherapy, Cancer Gene Ther, vol.11, pp.215-241, 2004.

T. Kapanadze, J. Gamrekelashvili, and C. Ma, Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma, J Hepatol, vol.59, pp.1007-1020, 2013.

E. Suzuki, V. Kapoor, and A. S. Jassar, Gemcitabine selectively eliminates splenic Gr-11/CD11b1 myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity, Clin Cancer Res, vol.11, pp.6713-6734, 2005.

P. A. Ascierto, E. Simeone, and M. Sznol, Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies, Semin Oncol, vol.37, pp.508-524, 2010.

J. Dubrot, F. Milheiro, and C. Alfaro, Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ, Cancer Immunol Immunother, vol.59, pp.1223-1256, 2010.

L. Niu, S. Strahotin, and B. Hewes, Cytokinemediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice, J Immunol, vol.178, pp.4194-213, 2007.